Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Core Insights - Prelude Therapeutics announced the first clinical data for PRT3789, a novel SMARCA2 degrader, targeting patients with advanced solid tumors having a SMARCA4 mutation [1][2] - The company is conducting a Phase 1 clinical trial to evaluate the safety, tolerability, and clinical activity of PRT3789, with enrollment on track and dose escalation expected to conclude by the end of 2024 [1][2] Clinical Trial Details - As of March 7, 2024, 40 patients have been enrolled in the trial, with 55% having loss-of-function mutations [2] - Dose escalation has progressed through 6 levels, ranging from 24 mg to 212 mg, with no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) reported [2] - Common adverse events include nausea (25%), constipation and dyspnea (17.5% each), decreased appetite and fatigue (15% each), and anemia (12.5%) [2] Clinical Activity Observations - Clinical activity noted includes RECIST partial responses, tumor shrinkage, and prolonged stable disease in patients with advanced esophageal cancer and non-small cell lung cancer (NSCLC) [2] - Dose-related increases in area under the curve (AUC) and decreases in SMARCA2 levels were observed, with minimal effects on SMARCA4 levels [2] Upcoming Events - Prelude Therapeutics will host an investor webcast on September 13, 2024, to discuss the findings and provide updates on the clinical trial [1][4] - Updated data will be presented at the European Society of Medical Oncology (ESMO) Congress 2024 [3] Company Overview - Prelude Therapeutics is focused on developing innovative precision oncology medicines, including first-in-class SMARCA2 degraders and a CDK9 inhibitor [5] - The company aims to address high unmet needs in cancer treatment through targeted protein degradation and next-generation therapies [5]